Perinatal Depression Triples Risk for Suicidal Behavior
12 Jan 2024
Clinical Result
FRIDAY, Jan. 12, 2024 -- Mothers with clinically diagnosed perinatal depression (PND) had a three times higher risk for suicidal behavior than mothers without perinatal depression, according to a study published online Jan. 9 in JAMA Network Open.
Hang Yu, from the Karolinska Institutet in Stockholm, and colleagues examined the association between PND and risk for short- and long-term suicidal behavior. The analysis included 86,551 women with PND (2001 to 2017) and 865,510 unaffected women individually matched on age and calendar year at delivery.
During a median 6.91 years of follow-up, the researchers found that more events of suicidal behavior (incidence rate [IR], 5.62 per 1,000 person-years) were identified among women with PND compared with unaffected women (IR, 1.01 per 1,000 person-years). Compared with unaffected women, women with PND also had an elevated risk for suicidal behavior (hazard ratio [HR], 3.15). Risk was somewhat attenuated when comparing PND women with their PND-free sisters (HR, 2.75). In a matched analysis, the association was greater for postnatal depression and among women without a history of psychiatric disorders. In the first year after diagnosis, the excess risk was pronounced (HR, 7.20), but remained statistically significant over five to 18 years of follow-up (HR, 2.34).
"These findings suggest that vigilant clinical monitoring and interventions are needed for this vulnerable population to prevent such devastating events," the authors write.
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Posted January 2024
More news resources
FDA Medwatch Drug Alerts
Daily MedNews
News for Health Professionals
New Drug Approvals
New Drug Applications
Drug Shortages
Clinical Trial Results
Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.